[5] [5] KONG Y, JING Y, SUN H, et al. The diagnostic value of contrast-enhanced ultrasound and enhanced CT combined with tumor markers AFP and CA199 in liver cancer[J]. J Healthc Eng, 2022, 2022: 5074571.

[7] [7] ZHANG C Y, ZHANG L, WANG Z M, et al. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers[J]. J Obstet Gynaecol, 2023, 43(1): 2213764.

[9] [9] TROJANO G, OLIVIERI C, TINELLI R, et al. Conservative treatment in early stage endometrial cancer: a review[J]. Acta Biomed, 2019, 90(4): 405-410.

[10] [10] GOWSKA-CIEMNY J, SZYMASKI M, KUSZERSKA A, et al. The role of alpha-fetoprotein (AFP) in contemporary oncology: the path from a diagnostic biomarker to an anticancer drug[J]. Int J Mol Sci, 2023, 24(3): 2539.

[11] [11] LIN B, DONG X, WANG Q, et al. AFP-inhibiting fragments for drug delivery: the promise and challenges of targeting therapeutics to cancers[J]. Front Cell Dev Biol, 2021, 9: 635476.

[12] [12] HE H, CHEN S, FAN Z, et al. Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma[J]. Cell Discov, 2023, 9(1): 60.

[17] [17] ZHANG J, ZHU Z, MIAO Z, et al. The clinical significance and mechanisms of REG4 in human cancers[J]. Front Oncol, 2021, 10: 559230.

[19] [19] GAO L, WU X, ZHANG L, et al. REG4 is a potential biomarker for radiochemotherapy sensitivity in colorectal cancer[J]. Onco Targets Ther, 2021, 14: 1605-1611.

[20] [20] XIANG L W, XUE H, HA M W, et al. The effects of REG4 expression on chemoresistance of ovarian cancer[J]. J Obstet Gynaecol, 2022, 42(7): 3149-3157.